Benjamin P. Saylor
Saylor is content managing editor for Urology Times.
Aortic calcification linked to heart disease in stone patients
Blood vessel calcification may increase risk of heart disease in patients with recurrent kidney stones, according to a recent study.
Drs. Gomella, Thrasher among 2015 AUA honorees
Two advisers to Urology Times are among the 2015 AUA annual award recipients.
Anticholinergic cycling not effective in OAB with UI
Anticholinergic cycling not effective in OAB with UI
The adage, “If at first you don’t succeed, try, try again,” does not appear to hold true when it comes to anticholinergic drug use in overactive bladder patients with urinary incontinence, recent study results indicate.
ICSI use doubles despite lack of improved outcomes
The analysis looked at intracytoplasmic sperm injection use and reproductive outcomes between 1996 and 2012. fertilization. Learn why
Analysis uncovers thousands of potential cancer markers
A newly published analysis “opens a huge opportunity for the discovery of new biomarkers” for multiple cancers, including aggressive prostate cancer, a leading urologic cancer expert says.
Medicare to cover another prostate Ca test
Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier, developer GenomeDx Biosciences reported.
Vaccine/androgen ablation combination found safe
Vaccine/androgen ablation combination found safe
A combination vaccine and androgen ablation therapy is showing promise in some patients with prostate cancer.
Testosterone shows benefit against advanced PCa
Testosterone shows benefit against advanced PCa
An advanced prostate cancer treatment protocol incorporating testosterone shows promise for treating the disease and reversing resistance to androgen deprivation therapy.
RT/hormone combo cuts PCa mortality in older men
The addition of radiation treatment to hormone therapy reduces mortality in older men with locally advanced prostate cancer compared with hormone therapy alone, according to a recently published study in the Journal of Clinical Oncology.
January 2015 Product Preview: FDA committee recommends approval of complicated UTI agent
Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.